Galeterone Synthesis via Filtration Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current synthesis processes for Galeterone, a compound useful for treating prostate cancer, are complex and not easily scalable for industrial production, with inefficient yields and purification methods that require flash chromatography.
Innovation Solution
A simplified synthesis route involving the reaction of 17-iodoandrosta-5,16-dien-3β-ol with benzimidazole in the presence of a base, cuprous iodide, and 8-hydroxyquinoline, followed by filtration with a physiologically acceptable acid to purify Galeterone, eliminating the need for chromatographic purifications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If flash chromatography is used for purification of intermediates, then purity of the product is improved, but device complexity and ease of manufacture deteriorate
Solution Approach 1:
The patent extracts and removes the problematic byproduct (compound 2) through selective chemical transformation. The Vilsmeier-Haack reaction conditions are optimized to favor formation of the desired intermediate (compound 3) while minimizing or eliminating the formation of unwanted byproducts, thereby removing the need for complex chromatographic separation equipment.
Solution Approach 2:
The patent modifies reaction parameters including temperature, solvent composition, reagent ratios, and reaction time to optimize the Vilsmeier-Haack reaction. These parameter changes improve selectivity and yield, allowing direct filtration-based purification instead of requiring flash chromatography, thus simplifying the manufacturing process.
2Reliability
If multiple reaction steps with intermediate purifications are used, then reliability of the synthesis is improved, but productivity deteriorates
Solution Approach 1:
The patent combines multiple reaction steps into a telescoped sequence where intermediates are carried forward without isolation. The Vilsmeier-Haack reaction conditions are designed to directly produce the reactive intermediate that can immediately undergo subsequent transformation, eliminating the need for separate purification steps and increasing overall productivity while maintaining reliability.
Solution Approach 2:
The patent performs preliminary optimization of reaction conditions to ensure high selectivity and yield in the Vilsmeier-Haack step. By pre-establishing optimal parameters for temperature, solvent, and reagent addition rates, the reaction reliably produces the desired intermediate in sufficient purity to proceed directly to the next step without intermediate purification.
3Quantity of substance
If Vilsmeier-Haack reaction is used to produce intermediate (2) and (3), then the desired intermediate (3) is formed, but unwanted byproduct (2) is also formed reducing productivity
Solution Approach 1:
The patent applies local quality control by optimizing specific aspects of the reaction environment including solvent selection, temperature gradients, and localized reagent addition. These localized optimizations enhance the selectivity of the Vilsmeier-Haack reaction, directing it preferentially toward formation of the desired intermediate (compound 3) while suppressing formation of the unwanted byproduct (compound 2).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves high purity levels of Galeterone without chromatographic purifications, making it suitable for pharmaceutical use and simplifying the industrial-scale production process.
Implementation Method 1
the reaction of 17-iodoandrosta-5,16-dien-3β-ol with benzimidazole in the presence of a base, cuprous iodide, and 8-hydroxyquinoline
Implementation Method 2
cuprous iodide, and 8-hydroxyquinoline
Data Source
AI summary
A process for the synthesis of β-hydroxy 3-17-(1H-benzimidazol-1-yl)androsta-5,16-diene is described, a compound also known as Galeterone and used in the treatment of prostate cancer, having the formula (6).